Baseline patient characteristics (n = 40)
| Characteristic . | Value . |
|---|---|
| Age, y, median (range) | 58 (29-69) |
| Female, no. (%) | 13 (33) |
| Stage III/IV, no. (%) | 40 (100) |
| Prior regimens, median (range) | 6 (3-12) |
| Prior transplant, no. (%) | 17 (43) |
| Chemosensitive, no. (%) | 6 (15) |
| CR, no. (%) | 0 (0) |
| Bulk > 5 cm, no. (%) | 17 (43) |
| > 25% marrow cellularity involved with NHL, no. (%) | 10 (25) |
| Baseline platelet count < 25 000/μL, no. (%) | 7 (18) |
| Comorbidity score ≥ 1, no. (%) | 34 (85) |
| International Prognostic Index at transplantation ≥ 3, no. (%) | 21 (53) |
| Histology, no. (%) | |
| Indolent | 18 (45) |
| De novo diffuse large B-cell | 7 (18) |
| Transformed diffuse large B-cell | 7 (18) |
| Mantle cell | 8 (20) |
| Donor, no. (%) | |
| Matched-related | 15 (38) |
| Matched-unrelated | 25 (62) |
| Characteristic . | Value . |
|---|---|
| Age, y, median (range) | 58 (29-69) |
| Female, no. (%) | 13 (33) |
| Stage III/IV, no. (%) | 40 (100) |
| Prior regimens, median (range) | 6 (3-12) |
| Prior transplant, no. (%) | 17 (43) |
| Chemosensitive, no. (%) | 6 (15) |
| CR, no. (%) | 0 (0) |
| Bulk > 5 cm, no. (%) | 17 (43) |
| > 25% marrow cellularity involved with NHL, no. (%) | 10 (25) |
| Baseline platelet count < 25 000/μL, no. (%) | 7 (18) |
| Comorbidity score ≥ 1, no. (%) | 34 (85) |
| International Prognostic Index at transplantation ≥ 3, no. (%) | 21 (53) |
| Histology, no. (%) | |
| Indolent | 18 (45) |
| De novo diffuse large B-cell | 7 (18) |
| Transformed diffuse large B-cell | 7 (18) |
| Mantle cell | 8 (20) |
| Donor, no. (%) | |
| Matched-related | 15 (38) |
| Matched-unrelated | 25 (62) |